FDA Approves Centocor's Remicade As First-Line Rheumatoid Arthritis Therapy

Self-Limited Autoimmune Syndrome Rare in Infliximab-Treated Patients 

European Committee Recommends Use Of Remicade (Infliximab) With Methotrexate For Rheumatoid Arthritis

Drug Mix Halts Joint Erosion In Persistent Arthritis

Back ] Up ] Next ]


The materials and information on this server are intended for educational and informational purposes only. The materials and information are not intended to replace the services of a trained health professional or to be a substitute for medical advice of physicians and/or other health care professionals. The International Still's Disease Foundation is not engaged in rendering medical or professional medical services. You should consult your physician on specific medical questions, particularly in matters requiring diagnosis or medical attention. The International Still's Disease Foundation makes no representations or warranties with respect to any treatment, action, application medication or preparation by any person following the information offered or provided within this website.  Any information used from other websites was done so with permission from each site, with an exception to those of "public domain", whereas we believe any site without a cited reference was a "public domain site" and for our use.  The International Still's Disease Foundation is a non-profit organization.   This page was last updated on January 17, 2001

Copyrightę 1999-2001 International Still's Disease Foundation